Characteristics of study populations
Variable . | Cohort 1, n = 297 . | Cohort 2, n = 38 . |
|---|---|---|
| Age, y, median (range) | ||
| Male | 67 (26–89) | 71 (39–91) |
| Female | 68 (23–90) | 72 (42–86) |
| Sex, n (%) | ||
| Male | 160 (54) | 19 (50) |
| Female | 137 (46) | 19 (50) |
| White, n (%) | 297 (100) | 38 (100) |
| Primary reason for anticoagulation, n (%) | ||
| AF | 191 (65) | 27 (71) |
| DVT/PE | 66 (22) | 8 (21) |
| Other | 40 (13) | 3 (8) |
| Daily warfarin dose, mg, mean (range) | 3.69 (0.3–10.75) | 3.78 (1.5–6.75) |
| CYP2C9 genotype, n (%) | ||
| *1*1 | 165 (56) | 29 (75) |
| *1*2 | 66 (22) | 4 (11) |
| *1*3 | 42 (14) | 4 (11) |
| *2*2 | 10 (3) | 0 (0) |
| *2*3 | 13 (4) | 1 (3) |
| *3*3 | 1 (<1) | 0 (0) |
| VKORC1 genotype, n (%) | ||
| GG | 74 (25) | 16 (42) |
| GA | 165 (56) | 17 (45) |
| AA | 58 (19) | 5 (13) |
Variable . | Cohort 1, n = 297 . | Cohort 2, n = 38 . |
|---|---|---|
| Age, y, median (range) | ||
| Male | 67 (26–89) | 71 (39–91) |
| Female | 68 (23–90) | 72 (42–86) |
| Sex, n (%) | ||
| Male | 160 (54) | 19 (50) |
| Female | 137 (46) | 19 (50) |
| White, n (%) | 297 (100) | 38 (100) |
| Primary reason for anticoagulation, n (%) | ||
| AF | 191 (65) | 27 (71) |
| DVT/PE | 66 (22) | 8 (21) |
| Other | 40 (13) | 3 (8) |
| Daily warfarin dose, mg, mean (range) | 3.69 (0.3–10.75) | 3.78 (1.5–6.75) |
| CYP2C9 genotype, n (%) | ||
| *1*1 | 165 (56) | 29 (75) |
| *1*2 | 66 (22) | 4 (11) |
| *1*3 | 42 (14) | 4 (11) |
| *2*2 | 10 (3) | 0 (0) |
| *2*3 | 13 (4) | 1 (3) |
| *3*3 | 1 (<1) | 0 (0) |
| VKORC1 genotype, n (%) | ||
| GG | 74 (25) | 16 (42) |
| GA | 165 (56) | 17 (45) |
| AA | 58 (19) | 5 (13) |
AF indicates atrial fibrillation; DVT, deep vein thrombosis; PE, pulmonary embolism.